- Clinical Trials
- April 2024
- 80 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- March 2018
- 280 Pages
Global
From €2308EUR$2,400USD£1,980GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Drug Pipelines
- October 2018
- 475 Pages
Global
From €21154EUR$22,000USD£18,147GBP
- Report
- November 2023
- 103 Pages
Global
From €3500EUR$3,899USD£3,108GBP
The Diffuse Large B Cell Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. It is composed of drugs used to treat Diffuse Large B Cell Lymphoma (DLBCL), a type of non-Hodgkin lymphoma. These drugs are typically used in combination with chemotherapy and/or radiation therapy. Common drugs used to treat DLBCL include rituximab, bendamustine, and obinutuzumab. These drugs are used to target the cancer cells and reduce the size of the tumor.
Some of the companies in the Diffuse Large B Cell Lymphoma Drug market include Roche, Novartis, Merck, Pfizer, and AbbVie. These companies are involved in the research, development, and marketing of drugs used to treat DLBCL. Show Less Read more
